Nov 17, 2025 • GlobeNewswire
NEUTRAL
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® ( zanidatamab-hrii ) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
VANCOUVER, British Columbia, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Oct 28, 2025 • GlobeNewswire
NEUTRAL
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Oct 28, 2025 • Benzinga
NEUTRAL
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Oct 23, 2025 • South China Morning Post
NEUTRAL
BeOne Medicines to expand cancer-drug offerings in Hong Kong
BeOne Medicines, a global drug company that originated in mainland China, plans to launch more cancer drugs in Hong Kong and expand production in Guangzhou to tap greater market opportunities arising from local drug-approval reforms two years ago.
Oct 23, 2025 • GlobeNewswire
NEUTRAL
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
VANCOUVER, British Columbia, Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Oct 16, 2025 • GlobeNewswire
NEUTRAL
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
VANCOUVER, British Columbia, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...